Table 2.
Genotyping of the five SNPs among the two studied groups of patients.
| Total (n = 224) | Recurrence (n = 58) | Non Recurrence (n = 166) | χ2 | p | |
|---|---|---|---|---|---|
| ABO | |||||
| O | 71 (31.7%) | 15 (25.9%) | 56 (33.7%) | χ2 = 24.189 * | <0.001 * |
| A | 67 (29.9%) | 15 (25.9%) | 52 (31.3%) | ||
| B | 60 (26.8%) | 11 (19%) | 49 (29.5%) | ||
| AB | 26 (11.6%) | 17 (29.3%) | 9 (5.4%) | ||
| Non O | 153 (68.3%) | 43 (74.1%) | 110(66.3%) | χ2 = 1.231 | 0.267 |
| FVR506 Q | |||||
| RR | 163 (72.8%) | 35 (60.3%) | 128 (77.1%) | 7.684 * | MCp = 0.011 * |
| RQ | 60 (26.8%) | 22 (37.9%) | 38 (22.9%) | ||
| 1 (0.4%) | 1 (1.7%) | 0 (0%) | |||
| RQ + QQ | 61(27.2%) | 23(39.7%) | 38 (22.9%) | 6.095 * | 0.014 * |
| FIIG20210 A | |||||
| GG | 199 (88.8%) | 49 (84.5%) | 150 (90.4%) | 1.498 | 0.221 |
| GA | 25 (11.2%) | 9 (15.5%) | 16 (9.6%) | ||
| AA | 0(0%) | 0(0%) | 0(0%) | ||
| GA + AA | 25 (11.2%) | 9 (15.5%) | 16 (9.6%) | 1.498 | 0.221 |
| FG G | |||||
| CC | 134 (59.8%) | 30 (51.7%) | 104 (62.7%) | 5.257 | 0.072 |
| CT | 68 (30.4%) | 18 (31%) | 50 (30.1%) | ||
| TT | 22 (9.8%) | 10 (17.2%) | 12 (7.2%) | ||
| CT + TT | 90(40.2%) | 28(48.3%) | 62(37.3%) | 2.135 | 0.144 |
| FX I | |||||
| TT | 112 (50%) | 26 (44.8%) | 86 (51.8%) | 8.473 * | 0.014 * |
| CT | 91 (40.6%) | 21 (36.2%) | 70 (42.2%) | ||
| CC | 21 (9.4%) | 11 (19%) | 10 (6%) | ||
| CT + CC | 112(50%) | 32(55.2%) | 80(48.2%) | 0.838 | 0.360 |
χ2: Chi square test; MC: Monte Carlo; * Statistically significant at p ≤ 0.05.